id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S12871 R48604 |
Thomas (Topiramate) (Controls exposed to Lamotrigine, sick), 2021 | Cardiac malformations | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
1.90 [0.07;50.68] C excluded (control group) |
0/9 1/50 | 1 | 9 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12872 R48614 |
Thomas (Topiramate) (Controls unexposed, sick), 2021 | Cardiac malformations | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 2.05 [0.11;38.10] C | 0/9 9/340 | 9 | 9 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S7662 R22677 |
Tomson (Topiramate), 2018 | Cardiac malformations | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 3.35 [0.96;11.71] C | 3/152 15/2,514 | 18 | 152 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9837 R37712 |
Vajda (Topiramate) (Controls exposed to Lamotrigine, sick), 2013 | Cardiac Malformations | at least 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
1.02 [0.05;20.14] C excluded (control group) |
0/44 3/315 | 3 | 44 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9838 R37716 |
Vajda (Topiramate) (Controls unexposed, sick), 2013 | Cardiac Malformations | at least 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 1.11 [0.04;27.86] C | 0/44 1/147 | 1 | 44 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S6061 R15760 |
Morrow (Topiramate) (Controls exposed to Lamotrigine, sick), 2006 | Cardiac | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 2.60 [0.14;49.43] C | 0/28 4/647 | 4 | 28 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 4 studies | 2.75 [0.99;7.59] | 32 | 233 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Topiramate) (Controls unexposed, sick; 2: Topiramate; 3: Topiramate) (Controls unexposed, sick; 4: Topiramate) (Controls exposed to Lamotrigine, sick;
Asymetry test p-value = NaN (by Egger's regression)
not enought points
excluded 9837, 12871